Also found in: Encyclopedia.
ARQAutomatic Repeat-reQuest
ARQArquitecto (Portuguese)
ARQArquitecto (Spanish)
ARQAutomatic Repeat Request
ARQAdmission Request
ARQAutomatic Request
ARQAsking the Right Questions
ARQAutomatic Request for Repetition
ARQAutomatic Repeat Queuing
ARQAutomatic Retransmission on Request
ARQAutomated Response to Query
ARQAdvancing and Recognizing Quality (National School Age Care Alliance)
ARQAnnual Review Questionnaire
ARQAviation Readiness Qualification
ARQAutomatic Retransmission Queue
ARQAuto Rate Quote (insurance)
ARQAutomatic Repeat Request/Query
ARQAddress Resolution Query
ARQAutomated Request to Query
References in periodicals archive ?
The DOZER ARQ technology, which differs from competing FEC offers, achieves TCP/IP's reliability without the overhead, making it ideal for demanding real-time applications like streaming video.
The process of developing adaptive ARQ scheme has two main stages:
As described above, increasing the frame size usually induces a high FER in the ARQ approach.
ARQ 197 is the lead product from ArQule's new kinase inhibitor discovery program.
We are excited to enter into a partnership with a world-class Japanese company whose oncology franchise positions it strongly in Asian markets and whose resources will allow it to develop and commercialize ARQ 197 on a timely basis," said Dr.
The company added ARQ 197 is an investigational selective inhibitor of the c-Met receptor tyrosine kinase in combination with erlotinib that is currently in Phase 2 and Phase 3 clinical trials and is not yet approved for use.
Preclinical data suggests ARQ 531 has the potential for broad clinical utility in a wide range of hematological malignancies and lymphomas.
M2 EQUITYBITES-December 7, 2010-ArQule Inc doses first patient in Phase 1 trial of ARQ 736(C)2010 M2 COMMUNICATIONS http://www.
For Tg 338 mice, the mean incubation period was 239 [+ or -] 32 days for the atypical scrapie isolate, and the incubation time for BSE prion previously passaged through ARQ/ ARQ sheep was 534 [+ or -] 25 days.
NASDAQ: ARQL) has dosed the first patient in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with Overgrowth Diseases driven by genetic alterations of the PI3K/AKT1 pathway, the company said.
M2 EQUITYBITES-October 12, 2010-ArQule Inc executes SPA agreement with FDA for Phase 3 trial of ARQ 197 for NSCLC(C)2010 M2 COMMUNICATIONS http://www.